Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
2.650
+0.330 (14.22%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Dogwood Therapeutics Employees
Dogwood Therapeutics had 8 employees as of December 31, 2025. The number of employees decreased by 4 or -33.33% compared to the previous year.
Employees
8
Change (1Y)
-4
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,505,161
Market Cap
90.08M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | -4 | -33.33% |
| Dec 31, 2024 | 12 | 8 | 200.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | -1 | -20.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| Fortress Biotech | 78 |
| Acrivon Therapeutics | 76 |
| ImmuCell | 73 |
| Cognition Therapeutics | 14 |
| Atara Biotherapeutics | 10 |
| Rallybio | 7 |
DWTX News
- 12 days ago - Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 - GlobeNewsWire
- 16 days ago - Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewsWire
- 16 days ago - Dogwood Therapeutics Earnings release: Q2 2026 - Filings
- 16 days ago - Dogwood Therapeutics Quarterly report: Q2 2026 - Filings
- 26 days ago - Dogwood Therapeutics Slides: Corporate presentation - Filings
- 5 weeks ago - Dogwood enrolls first 200 patients in HAL-CINP trial - TheFly
- 5 weeks ago - Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026 - GlobeNewsWire
- 2 months ago - Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board - GlobeNewsWire